CSIMarket
 


Horizon Therapeutics Public Limited Company  (HZNP)
Other Ticker:  
 
 

HZNP's Capital Expenditures Growth by Quarter and Year

Horizon Therapeutics Public Limited's Capital Expenditures results by quarter and year




HZNP Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 24.86 16.90 36.45
III Quarter September - 14.82 27.44 13.43
II Quarter June 18.47 10.15 13.92 0.97
I Quarter March 24.13 14.20 18.33 119.00
FY   42.60 64.03 76.59 169.85



HZNP Capital Expenditures second quarter 2023 Y/Y Growth Comment
Horizon Therapeutics Public Limited Company reported Capital Expenditures surge of 81.93% year on year in the second quarter 2023, to $ 18.47 millions, this is lower than Horizon Therapeutics Public Limited Company's recent average Capital Expenditures surge of 559.54%.

Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 56 other companies have achieved higher Capital Expenditures growth. While Horizon Therapeutics Public Limited Company' s Capital Expenditures jump of 81.93% ranks overall at the positon no. 656 in the second quarter 2023.




HZNP Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 47.1 % -53.64 % 458.19 %
III Quarter September - -45.99 % 104.32 % 200.45 %
II Quarter June 81.93 % -27.08 % 1335.05 % -80.64 %
I Quarter March 69.93 % -22.53 % -84.6 % 6332.43 %
FY   - -16.4 % -54.91 % 851.01 %

Financial Statements
Horizon Therapeutics Public Limited's second quarter 2023 Capital Expenditures $ 18.47 millions HZNP's Income Statement
Horizon Therapeutics Public Limited's second quarter 2022 Capital Expenditures $ 10.15 millions Quarterly HZNP's Income Statement
New: More HZNP's historic Capital Expenditures Growth >>


HZNP Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 67.75 % -38.41 % 171.41 %
III Quarter September - 46.01 % 97.13 % 1284.54 %
II Quarter June -23.47 % -28.52 % -24.06 % -99.18 %
I Quarter March -2.94 % -15.98 % -49.71 % 1722.36 %
FY (Year on Year)   - -16.4 % -54.91 % 851.01 %




Capital Expenditures second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #57
Healthcare Sector #135
Overall #656

Capital Expenditures Y/Y Growth Statistics
High Average Low
6336.13 % 559.54 % -91.96 %
(Mar 31 2020)   (Jun 30 2018)
Capital Expenditures second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #57
Healthcare Sector #135
Overall #656
Capital Expenditures Y/Y Growth Statistics
High Average Low
6336.13 % 559.54 % -91.96 %
(Mar 31 2020)   (Jun 30 2018)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Horizon Therapeutics Public Limited's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
3168.91 % 170.05 % -100 %
(Dec 31 2018)  


HZNP's II. Quarter Q/Q Capital Expenditures Comment
In the II. Quarter 2023 Horizon Therapeutics Public Limited Company realized fall in Capital Expenditures from the previous quarter by -23.47% to $ 18.47 millions, from $ 24.13 millions released a quarter before.

As we evaluate recent shortcoming at the II. Quarter, we must presume, that frequently II. Quarter 2023 results occur softer then in the first quarter

Within Major Pharmaceutical Preparations industry 50 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Horizon Therapeutics Public Limited's Capital Expenditures growth quarter on quarter, overall rank is 1308.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #51
Healthcare Sector #168
Overall #1308
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #51
Healthcare Sector #168
Overall #1308
Capital Expenditures Q/Q Growth Statistics
High Average Low
3168.91 % 170.05 % -100 %
(Dec 31 2018)  


HZNP's II. Quarter Q/Q Capital Expenditures Comment
In the II. Quarter 2023 Horizon Therapeutics Public Limited Company disclosed fall in Capital Expenditures from the previous quarter by -23.47% to $ 18.47 millions, from $ 24.13 millions achived in the previous quarter.

It's not important concern, as Capital Expenditures generally gravitate to dip in the II. Quarter Bryce P. Miller, Major Pharmaceutical Preparations industry insider allocated in Seattle noted.

Within Major Pharmaceutical Preparations industry 50 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Horizon Therapeutics Public Limited's Capital Expenditures growth quarter on quarter, overall rank is 1308.


Horizon Therapeutics Public Limited's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 82.27 $ 73.96 $ 64.03 $ 56.07 $ 68.69
Y / Y Capital Expenditures Growth (TTM) 19.76 % 2.06 % -16.41 % -41.68 % -16.37 %
Year on Year Capital Expenditures Growth Overall Ranking # 1321 # 1324 # 1769 # 2291 # 2337
Seqeuential Capital Expenditures Change (TTM) 11.24 % 15.51 % 14.19 % -18.38 % -5.2 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1571 # 1501 # 1525 # 2562 # 2574




Cumulative Capital Expenditures growth Comment
Although Horizon Therapeutics Public Limited's Annual Capital Expenditures growth year on year were below company's average 233.66% , Capital Expenditures announced in the Jun 30 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 19.76% year on year, from 2.06% in Mar 31 2023.

In the Healthcare sector 213 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1321, from total ranking in previous quarter at 1324.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
2167.2 %
233.66 %
-76.99 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 77
Healthcare Sector # 214
Overall # 1321

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
2167.2 %
233.66 %
-76.99 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 77
Sector # 231
S&P 500 # 1571
Cumulative Capital Expenditures growth Comment
Although Horizon Therapeutics Public Limited's Annual Capital Expenditures growth year on year were below company's average 233.66% , Capital Expenditures announced in the Jun 30 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 19.76% year on year, from 2.06% in Mar 31 2023.

In the Healthcare sector 213 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1321, from total ranking in previous quarter at 1324.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
2167.2 %
233.66 %
-76.99 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 77
Healthcare Sector # 214
Overall # 1321

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
2167.2 %
233.66 %
-76.99 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 77
Sector # 231
S&P 500 # 1571




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
HZNP's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for HZNP's Competitors
Capital Expenditures Growth for Horizon Therapeutics Public Limited's Suppliers
Capital Expenditures Growth for HZNP's Customers

You may also want to know
HZNP's Annual Growth Rates HZNP's Profitability Ratios HZNP's Asset Turnover Ratio HZNP's Dividend Growth
HZNP's Roe HZNP's Valuation Ratios HZNP's Financial Strength Ratios HZNP's Dividend Payout Ratio
HZNP's Roa HZNP's Inventory Turnover Ratio HZNP's Growth Rates HZNP's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Jun 30 2023
Shockwave Medical Inc 142.87%$ 142.865 millions
Bio rad Laboratories Inc 142.86%$ 142.859 millions
Beigene ltd 141.54%$ 141.539 millions
Pliant Therapeutics Inc 137.40%$ 137.402 millions
Alaunos Therapeutics Inc 136.84%$ 136.842 millions
Addus Homecare Corporation129.03%$ 129.032 millions
P3 Health Partners Inc 127.00%$ 127.001 millions
Igm Biosciences Inc 114.65%$ 114.646 millions
Icad Inc112.50%$ 112.500 millions
Orthofix Medical Inc 112.38%$ 112.376 millions
Vericel Corporation111.81%$ 111.812 millions
Longeveron Inc 111.34%$ 111.340 millions
Editas Medicine Inc 110.92%$ 110.918 millions
Iovance Biotherapeutics Inc 108.04%$ 108.042 millions
Caremax Inc 106.73%$ 106.732 millions
Dice Therapeutics Inc 105.27%$ 105.275 millions
Cryoport inc 103.47%$ 103.472 millions
Ocugen Inc 103.29%$ 103.294 millions
Denali Therapeutics Inc 102.21%$ 102.212 millions
Eli Lilly And Company98.98%$ 98.976 millions
Sarepta Therapeutics Inc 97.28%$ 97.279 millions
Entrada Therapeutics Inc 96.39%$ 96.387 millions
Psychemedics Corp93.10%$ 93.103 millions
Lifevantage Corp92.86%$ 92.857 millions
Biocryst Pharmaceuticals Inc 91.39%$ 91.393 millions
Petvivo Holdings Inc90.36%$ 90.360 millions
Fusion Pharmaceuticals Inc 89.33%$ 89.333 millions
Eiger Biopharmaceuticals Inc 88.89%$ 88.889 millions
Cutera Inc 86.37%$ 86.371 millions
Privia Health Group Inc 84.62%$ 84.615 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com